Aviceda's mission is to develop breakthrough glyco-therapeutics that modulate inflammation significantly by targeting the immune system’s natural self-recognition receptors to treat acute and chronic diseases of degeneration and inflammation, as well as diseases resulting from immune evasion.
Novel optimized nanoparticle that modulate innate immune dysfunction in AMD to prevent vision lossRead more
Glycobiology platform combined with proprietary nanoparticle technology to provide maximum efficacyRead more
What’s in a name you say? We say “Inspiration.” We take our name and inspiration from the Aviceda genus of birds renowned for their keen eyesight. Just like these birds of prey we never lose sight of the objective to bring transformative medicines to patients.
To bring transformative therapeutic strategies to the clinic that will cure disease, transform lives, and address significant unmet medical needs.
Aviceda Therapeutics is an innovative biotech company focused on harnessing the promise of immune cells’ natural checkpoints, which modulate innate immune activity that is dysregulated in a diverse range of diseases characterized by chronic non-resolving inflammation.
Glycome has much greater diversity than genome or proteome. Siglec-Sialic Acid Axis is like a combinatorial lock (Siglecs) requiring a code (Sialyloglycans) to modulate innate immune checkpoints.
Aviceda’s technology is predicated on engaging immunological switches that turn on and off pathologic mechanisms.
Aviceda's technology platform engineered a highly optimized glyco-ligands that can modulate the self-recognition receptors on immune cells profoundly and specifically and convert them to resolution state.
Aviceda’s lead candidate targets age-related macular degeneration (AMD), a disease that is driven by an aberrant immune-inflammatory response in the retina.
The formation of drusen on the retina is highly consequential for AMD pathogenesis: the innate immune system initiates inflammatory mediators to help remove the non-native drusen, but when it can no longer be effectively cleared, immune activity, and consequential release of pro-inflammatory signals, continues indefinitely in a pathologic cycle.
Aviceda’s AMD Therapeutic Strategy:
Aviceda’s Ophthalmics lead candidate, AVD-104, is being developed to target various immune system responses that contribute to pathology associated with dry AMD.
Aviceda Ophthalmics is developing a pipeline of GITs that are delivered via biodegradable nanoparticles and which safely and effectively target both cellular and humoral aspects of inflammatory processes in AMD.
The Aviceda team is comprised of world-class leaders in drug development, clinical sciences, drug discovery, clinical research, and finance to deliver disruptive, first-in-class & best-in-class therapeutics to a wide range of disease states.
Aviceda is partnering with world-renowned glyco-chemist Prof. Geert-Jan Boons and analytical glyco-biologist Dr. Parastoo Azadi and their teams at Complex Carbohydrate Research Center (CCRC) to spearhead development of the next generation of glyco-immune therapeutics.Full article
An internationally renowned group of scientists, researchers and clinicians will work with Aviceda’s in-house team to spearhead development of the next generation of glyco-immune therapeutics.Full article
Aviceda Therapeutics is building a world-class team of people dedicated to the discovery and development of novel drugs to treat patients with life threatening diseases. We seek highly motivated individuals who enjoy working in a collaborative atmosphere and a goal-oriented environment.
Aviceda is headquartered in Cambridge, Massachusetts with research partnership sites in Georgia and Belfast.